Endo International PLC (NASDAQ:ENDP) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $9.67 and last traded at $9.71, with a volume of 4,146,463 shares traded. The stock had previously closed at $9.91.

ENDP has been the subject of a number of recent analyst reports. Royal Bank Of Canada set a $15.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research report on Saturday, April 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $14.00 price objective on shares of Endo International PLC in a research report on Tuesday, April 11th. Mizuho reaffirmed a “buy” rating and issued a $18.00 price objective (up from $17.00) on shares of Endo International PLC in a research report on Thursday, April 13th. Vetr downgraded shares of Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 price objective for the company. in a research report on Thursday, April 27th. Finally, BMO Capital Markets reaffirmed a “hold” rating and issued a $15.00 price objective on shares of Endo International PLC in a research report on Monday, May 1st. Three research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $17.33.

The company’s 50 day moving average price is $11.45 and its 200 day moving average price is $11.76. The firm’s market cap is $2.11 billion.

Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.13. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.08 earnings per share. On average, equities analysts predict that Endo International PLC will post $3.54 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. OppenheimerFunds Inc. increased its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. First Quadrant L P CA purchased a new position in shares of Endo International PLC during the first quarter valued at $24,556,000. Schneider Capital Management Corp increased its position in shares of Endo International PLC by 14.9% in the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock valued at $7,168,000 after buying an additional 83,100 shares in the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Endo International PLC by 93.4% in the second quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock valued at $6,314,000 after buying an additional 273,024 shares in the last quarter. 92.83% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Endo International PLC (ENDP) Sets New 12-Month Low at $9.67” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/08/04/endo-international-plc-endp-sets-new-12-month-low-at-9-67.html.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.